All Stories

  1. Beyond Nonverbal Learning Disability: The Case for and Against Developmental Visual–Spatial Disorder as a Distinct Diagnosis
  2. “Schizophrenia, Consciousness, and the Self” Twenty Years Later: Revisiting the Ipseity-Disturbance Model and the Developmental Nature of Self-Disorder in the Schizophrenia Spectrum
  3. Lack of transparency on baseline pharmacological treatments in Clinical High-Risk for psychosis (CHR-P) may degrade precision: A systematic review and meta-analysis
  4. Increasing conceptual clarity and confounders identification: a pragmatic way to enhance prognostic precision in ENIGMA clinical high risk for psychosis (CHR-P)
  5. Early intervention in eating disorders: introducing the chronopathogram
  6. L’espace vécu and Its Perturbations in Schizophrenia: Systematic Review and Meta-analysis of Altered Body-Centric Metrics—Personal and Peripersonal Space
  7. Baseline benzodiazepine exposure is associated with greater risk of transition in clinical high-risk for psychosis (CHR-P): a meta-analysis
  8. The temporal dynamics of transition to psychosis in individuals at clinical high-risk (CHR-P) shows negative prognostic effects of baseline antipsychotic exposure: a meta-analysis
  9. Faraway So Close: Schizophrenia and Dissociation From Clinical, Phenomenological, and Ontogenetic Viewpoints
  10. Clinical High Risk for Psychosis (CHR-P) in children and adolescents: a roadmap to strengthen clinical utility through conceptual clarity
  11. Neurodevelopmental Antecedents and Sensory Phenomena in Obsessive Compulsive Disorder: A Systematic Review Supporting a Phenomenological-Developmental Model
  12. Do antidepressants prevent transition to psychosis in individuals at clinical high-risk (CHR-P)? Systematic review and meta-analysis
  13. Vaccine Hesitancy, Anti-Vax, COVID-Conspirationism: From Subcultural Convergence to Public Health and Bioethical Problems
  14. Clinical high risk for psychosis in children and adolescents: A meta-analysis of transition prevalences
  15. From economic crisis and climate change through COVID-19 pandemic to Ukraine war: a cumulative hit-wave on adolescent future thinking and mental well-being
  16. Association between psychosocial interventions and aberrant salience in adolescents with early psychosis: A follow‐up study
  17. (Developmental) Motor Signs: Reconceptualizing a Potential Transdiagnostic Marker of Psychopathological Vulnerability
  18. Antipsychotics in Children and Adolescents at Clinical High Risk for Psychosis
  19. Examining subjective experience of aberrant salience in young individuals at ultra-high risk (UHR) of psychosis: A 1-year longitudinal study
  20. Through the prism of comorbidity: A strategic rethinking of early intervention in obsessive-compulsive disorder
  21. Identifying adolescents in the early stage of psychosis: A screening checklist for referrers
  22. Aberrant salience in first‐episode psychosis: Longitudinal stability and treatment‐response
  23. Letter to the Editor: Skin-Testing for Clones—Pediatric Obsessive Compulsive Disorder with Misidentification Syndrome
  24. Applying Transgenerational Scientific Evidence to the Next Wave of Early Identification Strategies for Psychopathological Risk—Transdiagnostic, Developmental, and Personalized
  25. Individualized Diagnostic and Prognostic Models for Psychosis Risk Syndromes: Do Not Underestimate Antipsychotic Exposure
  26. Reply to: Individualized Diagnostic and Prognostic Models for Psychosis Risk Syndromes: Do Not Underestimate Antipsychotic Exposure
  27. Subjective experience of aberrant salience in young people at Ultra-High Risk (UHR) for psychosis: a cross-sectional study
  28. Editorial Perspective: Psychosis risk in adolescence – outcomes, comorbidity, and antipsychotics
  29. Along the fringes of Agency: neurodevelopmental account of the obsessive mind
  30. Negative Prognostic Effect of Baseline Antipsychotic Exposure in Clinical High Risk for Psychosis (CHR-P): Is Pre-Test Risk Enrichment the Hidden Culprit?
  31. ANHEDONIA IN THE PSYCHOSIS RISK SYNDROME: STATE AND TRAIT CHARACTERISTICS
  32. Towards a phenomenological and developmental clinical staging of the mind with psychosis
  33. Early intervention in psychiatry through a developmental perspective
  34. Coronavirus Disease 2019 and Effects of School Closure for Children and Their Families
  35. The Self in the Spectrum: A Meta-analysis of the Evidence Linking Basic Self-Disorders and Schizophrenia
  36. Antipsychotic treatment in clinical high risk for psychosis: Protective, iatrogenic or further risk flag?
  37. Familiarity for Serious Mental Illness in Help-Seeking Adolescents at Clinical High Risk of Psychosis
  38. Feasibility and effectiveness of Dialectical-Behavior Therapy for patients with borderline personality disorder in Italian mental health services: a preliminary study
  39. Editorial Perspective: Rethinking child and adolescent mental health care after COVID‐19
  40. Overcoming the gap between child and adult mental health services: The Reggio Emilia experience in an early intervention in psychosis program
  41. Attenuated Psychosis Syndrome or Pharmacologically Attenuated First-Episode Psychosis?
  42. Negative symptom dimensions in first episode psychosis: Is there a difference between schizophrenia and non‐schizophrenia spectrum disorders?
  43. Meta-analyzing the prevalence and prognostic effect of antipsychotic exposure in clinical high-risk (CHR): when things are not what they seem
  44. Psychological Support to the Community During the COVID-19 Pandemic: Field Experience in Reggio Emilia, Northern Italy
  45. Managing COVID‐19‐related psychological distress in health workers: Field experience in northern Italy
  46. Looking at Intergenerational Risk Factors in Schizophrenia Spectrum Disorders: New Frontiers for Early Vulnerability Identification?
  47. Assessing aberrant salience in young community help‐seekers with early psychosis: The approved Italian version of the Aberrant Salience Inventory
  48. Childhood schizotypal features vs. high-functioning autism spectrum disorder: Developmental overlaps and phenomenological differences
  49. Hey teachers! Do not leave them kids alone! Envisioning schools during and after the coronavirus (COVID-19) pandemic
  50. Advances in early identification of children and adolescents at risk for psychiatric illness
  51. Subjective experience of social cognition in young people at Ultra-High Risk of psychosis: a 2-year longitudinal study
  52. Disembodiment and schizophrenia: Looking at the motor roots of minimal self disorders in a developmental perspective
  53. Developmental Psychotic Risk: Toward a Neurodevelopmentally Informed Staging of Vulnerability to Psychosis
  54. Suicide risk in young people at Ultra-High Risk (UHR) of psychosis: Findings from a 2-year longitudinal study
  55. Suicidal thinking and behaviours in First Episode Psychosis: Findings from a 3‐year longitudinal study
  56. Letter to the editor: Evidence on school closure and children’s social contact: useful for coronavirus disease (COVID-19)?
  57. Anhedonia in young people with first episode psychosis: a longitudinal study
  58. Subjective experience of social cognition in adolescents at ultra-high risk of psychosis: findings from a 24-month follow-up study
  59. Overlooking the transition elephant in the ultra-high-risk room: are we missing functional equivalents of transition to psychosis?
  60. Characterization of young people with first episode psychosis or at ultra-high risk: the Reggio Emilia At-Risk Mental States (ReARMS) program
  61. Obsessively thinking through the schizophrenia spectrum: Disentangling pseudo-obsessive schizophrenia from OCD
  62. Impaired Corollary Discharge in Psychosis and At-Risk States: Integrating Neurodevelopmental, Phenomenological, and Clinical Perspectives
  63. Developmental dynamic interplay between executive functions and psychotic risk
  64. The “Reggio Emilia At‐Risk Mental States” program: A diffused, “liquid” model of early intervention in psychosis implemented in an Italian Department of Mental Health
  65. Anhedonia in adolescents at ultra-high risk (UHR) of psychosis: findings from a 1-year longitudinal study
  66. Social dysfunction in preclinical, at risk stages of psychosis: A developmental view
  67. Suicidal Thinking and Behavior in Adolescents at Ultra‐High Risk of Psychosis: A Two‐year Longitudinal Study
  68. Intruding Thoughts: Between Obsessions and Hallucinations
  69. Uncanny Mirroring: A Developmental Perspective on the Neurocognitive Origins of Self-Disorders in Schizophrenia
  70. Clinical high risk for psychosis in childhood and adolescence: findings from the 2-year follow-up of the ReARMS project
  71. Considerations on Retrospective Identification and Classification of Learning Disabilities
  72. Polygenic Risk Score and the (neuro)developmental ontogenesis of the schizophrenia spectrum vulnerability phenotypes
  73. Rethinking the Psychosis Threshold in Clinical High Risk
  74. Calculation of the sound field due to circular rigid and resilient disks using spherical expansions.
  75. Motor Impairment and Developmental Psychotic Risk: Connecting the Dots and Narrowing the Pathophysiological Gap
  76. Clinical Implications of Slower Cognitive Growth in the Psychosis Spectrum
  77. Editorial Perspective: From schizophrenia polygenic risk score to vulnerability (endo‐)phenotypes: translational pathways in child and adolescent mental health
  78. A research framework to isolate visuospatial from childhood motor coordination phenotypes
  79. 28.2 DISORDERS OF THE EMBODIED SELF IN SCHIZOPHRENIA: AT THE CROSSROAD BETWEEN DEVELOPMENT AND PSYCHOPATHOLOGY
  80. Screening for psychosis risk among help‐seeking adolescents: Application of the Italian version of the 16‐item prodromal questionnaire (iPQ‐16) in child and adolescent neuropsychiatry services
  81. Corollary Discharge and Psychosis—Origin of the Model—Reply
  82. Stably positive Lyapunov exponents for symplectic linear cocycles over partially hyperbolic diffeomorphisms
  83. The Italian Version of the Brief 21-Item Prodromal Questionnaire: Field Test, Psychometric Properties and Age-Sensitive Cut-Offs
  84. Corollary Discharge, Self-agency, and the Neurodevelopment of the Psychotic Mind
  85. Internet of Things as a means to improve agricultural sustainability
  86. Architecture of change: rethinking child and adolescent mental health
  87. Rethinking Social Agent Representation in the Light of Phenomenology
  88. The dark side of dopaminergic therapies in Parkinson’s disease: shedding light on aberrant salience
  89. Schizophrenia polygenic risk score and psychotic risk detection
  90. Developmental Coordination Disorder Plus Oculomotor and Visuospatial Impairment as Neurodevelopmental Heralds of Psychosis Proneness
  91. Cognitive Clusters in Specific Learning Disorder
  92. Detecting dysexecutive syndrome in neurodegenerative diseases: are we using an appropriate approach and effective diagnostic tools?
  93. Definition of a visuospatial dimension as a step forward in the diagnostic puzzle of nonverbal learning disability
  94. Cortical thickness in de novo patients with Parkinson disease and mild cognitive impairment with consideration of clinical phenotype and motor laterality
  95. Migraine features in migraineurs with and without anxiety–depression symptoms: A hospital-based study
  96. Concomitant development of hypersexuality and delusional jealousy in patients with Parkinson's disease: A case series
  97. WISC-IV Intellectual Profiles in Italian Children With Specific Learning Disorder and Related Impairments in Reading, Written Expression, and Mathematics
  98. A pilot psychometric study of aberrant salience state in patients with Parkinson’s disease and its association with dopamine replacement therapy
  99. Mild Depressive Symptoms are Associated With Enhanced Affective Theory of Mind in Nonclinical Adult Women
  100. Progression of brain atrophy in the early stages of Parkinson's disease: A longitudinal tensor-based morphometry study in de novo patients without cognitive impairment
  101. Validation and attempts of revision of the MDS-recommended tests for the screening of Parkinson's disease dementia
  102. Diagnosis of possible Mild Cognitive Impairment in Parkinson's disease: Validity of the SCOPA-Cog
  103. The development of delusion revisited: A transdiagnostic framework
  104. A Single-Center, Cross-Sectional Prevalence Study of Impulse Control Disorders in Parkinson Disease
  105. Affective theory of mind in patients with Parkinson's disease
  106. Reply: Dopamine agonists and delusional jealousy in Parkinson's disease: A cross‐sectional prevalence study
  107. Corticobasal Syndrome Presenting With Partial Gerstmann’s Syndrome and Digit Agnosia
  108. From Aberrant Salience to Jumping to Conclusions
  109. Progressive Impairment of Decision-Making in Behavioral-Variant Frontotemporal Dementia
  110. Cognitive correlates of negative symptoms in behavioral variant frontotemporal dementia: implications for the frontal lobe syndrome
  111. How Aware Are Migraineurs of Their Triggers?
  112. Lo spettro psicopatologico nella variante comportamentale della demenza frontotemporale
  113. Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson’s disease
  114. The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naïve patients with Parkinson's disease
  115. Neural and behavioral substrates of subtypes of Parkinson’s disease
  116. Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson�s disease-in Parkinson�s disease-Cognition (SCOPA-Cog)
  117. Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson�s disease-in Parkinson�s disease- Cognition (SCOPA-Cog)
  118. Diagnosis, assessment and management of delusional jealousy in Parkinson’s disease with and without dementia
  119. Triggers in Allodynic and Non‐Allodynic Migraineurs. A Clinic Setting Study
  120. Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson’s disease: a review
  121. Prefrontal cortex, dopamine, and jealousy endophenotype
  122. Behavioral and Psychological Symptoms of Dementia: Factor Analysis and Relationship with Cognitive Impairment
  123. Alteration of affective Theory of Mind in amnestic mild cognitive impairment
  124. Dopamine agonists and delusional jealousy in Parkinson's disease: A cross‐sectional prevalence study
  125. Mild cognitive impairment in De Novo Parkinson's disease according to movement disorder guidelines
  126. Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction
  127. Alexithymia Is Associated With Impulsivity in Newly-Diagnosed, Drug-Naïve Patients With Parkinson’s Disease: An Affective Risk Factor for the Development of Impulse-Control Disorders?
  128. Cognitive and affective Theory of Mind in neurodegenerative diseases: Neuropsychological, neuroanatomical and neurochemical levels
  129. Relationship Between Neuropsychiatric Symptoms and Cognitive Performance in De Novo Parkinson’s Disease
  130. The “Closing-In” Phenomenon in Parkinson’s Disease Dementia and Lewy-Body Dementia
  131. Affective symptoms and cognitive functions in Parkinson's disease
  132. Orbital and ventromedial prefrontal cortex functioning in Parkinson’s disease: Neuropsychological evidence
  133. Impulse control disorders in Parkinson’ disease: the role of personality and cognitive status
  134. Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease
  135. Impairment of Affective Theory of Mind in Corticobasal Degeneration
  136. Personality traits in patients with Parkinson’s disease: assessment and clinical implications
  137. Iowa gambling task in de novo Parkinson's disease: A comparison between good and poor performers
  138. Event-Based Prospective Memory in Newly Diagnosed, Drug-Naive Parkinson's Disease Patients
  139. Mild cognitive impairment and cognitive reserve in Parkinson’s disease
  140. Impulsivity Is Associated With Decision-Making Deficits in De-Novo Parkinson's Disease
  141. Theory of Mind in Parkinson's disease
  142. The neuropsychological correlates of pathological lying: evidence from behavioral variant frontotemporal dementia
  143. Decision-Making Impairment May Precede Limb Apraxia in Corticobasal Degeneration
  144. Impulsivity and compulsivity in drug‐naïve patients with Parkinson's disease
  145. Alexithymia Is Associated with Depression in de novo Parkinson’s Disease
  146. From Narcissistic Personality Disorder to Frontotemporal Dementia: A Case Report
  147. The association between motor subtypes and alexithymia in de novo Parkinson’s disease
  148. Iowa Gambling Task in Parkinson's Disease
  149. Decision making in de novo Parkinson's disease
  150. Out-of-Control Sexual Behavior in an Orbitofrontal Cortex-Damaged Elderly Patient
  151. Orbitofrontal cortex-related executive functions in children and adolescents: their assessment and its ecological validity
  152. Out-of-Control Sexual Behavior in an Orbitofrontal Cortex-Damaged Elderly Patient
  153. Decision-Making Impairment in a Patient With New Concomitant Diagnoses of Parkinson's Disease and HIV
  154. Decision-Making Impairment in a Patient With New Concomitant Diagnoses of Parkinson’s Disease and HIV
  155. Gestural buffer impairment in early onset Corticobasal Degeneration: a single-case study